Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
Completed
Sanofi
Phase 2
2013-02-01
This Phase 2 study was intended to assess the pharmacodynamics (PD), pharmacokinetics (PK),
safety and efficacy of sotagliflozin following daily oral administration for 29 days in
participants with type 1 diabetes mellitus (T1DM).
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
Completed
Lexicon Pharmaceuticals
Phase 2
2013-02-01
This Phase 2 study was intended to assess the pharmacodynamics (PD), pharmacokinetics (PK),
safety and efficacy of sotagliflozin following daily oral administration for 29 days in
participants with type 1 diabetes mellitus (T1DM).
Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C
Completed
Juvenile Diabetes Research Foundation
Phase 2
2015-04-01
This Phase 2 study was intended to demonstrate superiority of sotagliflozin versus placebo on
Hemoglobin A1C (A1C) reduction at Week 12 in young adult participants with type 1 diabetes
mellitus (T1DM) who have poor glycemic control on their current insulin regimen.
Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C
Completed
Sanofi
Phase 2
2015-04-01
This Phase 2 study was intended to demonstrate superiority of sotagliflozin versus placebo on
Hemoglobin A1C (A1C) reduction at Week 12 in young adult participants with type 1 diabetes
mellitus (T1DM) who have poor glycemic control on their current insulin regimen.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
